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Left ventricular hypertrophy in renal failure. In patients with
terminal renal failure, left ventricular hypertrophy (LVH) is
extremely common. It is found in approximately 60 to 80% of
patients starting renal replacement therapy. The main causes of
LVH are increased preload from hypervolemia and increased
afterload from increased peripheral resistance, giving rise to a
mixture of excentric and concentric hypertrophy, but other factors
(high cardiac output from anemia and arteriovenous (A-V)
fistula, altered compliance of central arteries, and activation of
local systems such as renin and endothelin) also play a role. The
clinical importance of LVH derives from the fact that LVH is a
predictor of cardiac death in dialyzed patients independent of
blood pressure. LVH is accompanied by microvascular disease
and by marked interstitial fibrosis (more than seen in non-renal
patients with similar degrees of hypertension). Recent findings
suggest that LV remodeling starts early and is seen even in
normotensive patients with glomerulonephritis when GFR is still
normal. The strategies to reduce LVH include reduction of
hypervolemia, (near) normalization of hemoglobin and lowering
of blood pressure, particularly by administration of angiotensin
converting enzyme inhibitors.
EPIDEMIOLOGY OF LEFT VENTRICULAR
HYPERTROPHY IN RENAL FAILURE
Left ventricular hypertrophy (LVH) is one of the major
cardiovascular complications of end-stage renal failure.
There is consensus that echocardiography is the gold
standard for diagnosing LVH. A number of recent studies
[1–4] document the high frequency of this condition in
patients entering renal replacement therapy, that is, be-
tween 60% [2] and 80% [3]. Left ventricular mass increases
progressively with duration of dialysis treatment even in
normotensive patients [5]. Particularly in patients with
incipient LVH, asymmetric septal hypertrophy (ASH) may
be encountered [6]. The patient usually has a mixture of
concentric and excentric hypertrophy, which reflects the
variable contributions of increased preload and afterload
[4].
Increased LVH persist even after renal transplantation
[7], and a relationship between blood pressure and LVH is
found even in normotensive recipients of renal grafts.
The question emerges as to whether LVH is unique to
end-stage renal failure. As shown in Table 1, increased
septal thickness (mostly within the normal range) is found
even in the earliest stages of glomerular disease, that is, in
patients with IgA glomerulonephritis, non-nephrotic pro-
teinuria and normal inulin clearance who have blood
pressures within the range of normotension according to
WHO criteria [8]. Even at this early stage of glomerulone-
phritis, cardiac remodeling is accompanied by impaired
diastolic LV function as reflected by the ratio between early
diastolic/late diastolic (atrial contraction) inflow velocity
across the mitral valve.
CLINICAL SIGNIFICANCE OF LEFT VENTRICULAR
HYPERTROPHY
In patients with essential hypertension it has been well
established that LVH, independent of blood pressure, is
predictive of ventricular arrhythmia [9] and cardiac death
[10]. The same is true for uremic patients on maintenance
hemodialysis. Silberberg et al noted that the actuarial five
year survival rate is significantly higher (56 vs. 22%) in
patients with normal LV mass, that is, ,125 g/1.73 m2, as
opposed to patients with increased LV mass [11]. By
multivariate analysis, LV mass emerged as a predictor that
is independent of blood pressure.
LVH has a number of important clinical sequelae: (i)
impaired LV compliance; (ii) increased coronary resis-
tance; and (iii) arrhythmogenesis [12].
Left ventricular hypertrophy reduces compliance of the
left ventricle
Compliance of the left ventricle is impaired in LVH. As
a consequence of this action, cardiac filling is more sensi-
tive to changes in LV filling pressure. On the one hand,
hypervolemia will more readily cause an increase in left
atrial pressure and thus predispose the patient to pulmo-
nary edema. On the other hand, a decrease of LV filling
pressure, for example, during ultrafiltration, will predispose
the patient to an abrupt LV underfilling, reduced ejection
volume, tachycardia and hypotension (or else, if LV under-
filling activates the Bezold Jarisch reflex, it will predispose
the patient to vagovasal syncope and bradycardia). Ruff-
mann et al found a very significant relationship between
disturbed LV compliance, as assessed by transmitral inflow
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velocity (E/A ratio) and the propensity to intradialytic
hypotension [13]. This point is important because in a
prospective study intradialytic hypotension was identified
as a strong predictor of cardiac death [14].
Left ventricular hypertrophy also increases coronary
vascular resistance even in the absence of coronary
stenosis
Coronary vascular resistance is increased in LVH, even
in the absence of coronary stenosis. Such an increase in the
so-called “extravascular component” of coronary resistance
may be responsible for angina pectoris, despite patent
coronaries in patients with aortic stenosis. Similarly, 30 to
50% of dialysis patients with angina pectoris have patent
coronaries upon coronarography, as documented by Roig
et al [15] and Rostand, Kirk and Rutsky [16]. This tendency
to underperfusion is aggravated by the fact that a mismatch
between capillary supply and cardiomyocytes is found in
the heart of uremic patients (Table 2) [17].
Hypertrophied hearts are predisposed to develop
arrhythmia
Finally, hypertrophied hearts are predisposed to develop
arrhythmia [18, 19] through various mechanisms.
PATHOMECHANISMS OF LEFT VENTRICULAR
HYPERTROPHY IN RENAL FAILURE
In renal failure, both preload and afterload are increased
because of hypervolemia and increased peripheral vascular
resistance respectively. As illustrated schematically in Fig-
ure 1, an increase in preload, induced by hypervolemia,
causes serial addition of sarcomers leading to lengthening
of myofibers and excentric hypertrophy.
In contrast, increased afterload, such as, from increased
peripheral resistance and increased impedance, causes
parallel addition of sarcomers, thickening of myofibers and
concentric hypertrophy.
In contrast to “physiological hypertrophy” as encoun-
tered, for instance, in athletes (“athletes’ heart”), patho-
logical forms of left ventricular hypertrophy are accompa-
nied by interstitial fibrosis (Fig. 2). Dilated cardiomyopathy
Fig. 1. Schema of the genesis (top) and
sequelae (bottom) of left ventricular
hypertrophy in renal failure.
Table 1. Findings in normotensive (,140/90 mm Hg) patients with IgA
glomerulonephritis with normal inulin clearance (CIn) and non-
nephrotic proteinuria [8]






IgA-GN 95 93 9.0 1.7
(N 5 20) (83–105) (82–100) (7.0–12.0) (1.03–2.42)
Matched controls 90 81.5 8.0 2.29
(N 5 20) (75–110) (78–96) (7.9–9.5) (1.6–3.19)
P 0.02 0.0005 0.001 0.0003
a Ratio of early diastolic inflow rate/inflow rate during atrial contraction
Table 2. Capillary density in the hearts of uremic patients [17]
Length density of capillaries [LV]
a
mm/mm3
Controls 2898 6 456
(N 5 10)
Essential hypertension 1872 6 243b
(N 5 9)
Uremia 1483 6 283b,c
(N 5 9)
a Total length (mm) of all capillaries contained in one unit volume
(mm3) of heart tissue
b P , 0.001 vs. control
c P , 0.05 vs. essential hypertension
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and systolic pump failure supervene when the mass of
working myocardium is reduced through single cell necro-
sis, through patchy necrosis [12] and—as our experiments
also suggest—through apoptosis [20].
PATHOMECHANISMS OF LEFT VENTRICULAR
HYPERTROPHY IN RENAL FAILURE
Apart from hypervolemia and hypertension, which are
undoubtedly the key factors in the genesis of LVH, several
other mechanisms come into play [21]. These comprise
high cardiac output as a result of anemia and the arterio-
venous (A-V) fistula, disturbed elasticity of the central
arteries with elevated impedance, and possibly activation of
local systems, such as the renin or endothelin systems [12].
Many authors found a correlation between the hemoglo-
bin (Hb) concentration and LV mass in dialyzed patients
[2]. On the other hand, partial reversal of anemia through
administration of recombinant human erythropoietin
(rHuEPO) reduced left ventricular mass (LVM), but failed
to normalize it [11, 22, 23]. Since Hb was not normalized, it
is uncertain whether complete normalization of Hb may
cause a further decrease of LVM; this issue is currently the
object of several controlled studies [24].
By multivariate analysis, London et al further identified
Fig. 2. Heart of a patient with chronic renal
failure. Note hypertrophy of cardiomyocytes
and diffuse interstitial fibrosis (HE stain,
paraffin section; magnification 1:250).
Fig. 3. Expression of endothelin 1 in the
myocardial interstitium of a patient with renal
failure of 20 years duration.
(Immunohistochemistry, paraffin section;
magnification 1:150).
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cardiac output as an important contributor to LVH [21]. It
may be increased as a function of hypervolemia, anemia
and A-V fistula.
Abnormal interaction (coupling) between the heart and
central arteries will be discussed below [25, 26].
Recent studies in our laboratory showed that experimen-
tal uremia is associated with increased expression of renin
mRNA (by in situ hybridization), endothelin-1 (by immu-
nohistochemistry) [12], and a variety of cytokines and
cytokine receptors as summarized in Table 3 [27]. It is of
interest that endothelin receptor antagonists prevent inter-
stitial fibrosis (Fig. 3) and the reduction in capillary length
density, that is, capillary supply, in the heart of subtotally
nephrectomized rats (Fig. 4).
ROLE OF A FAULTY INTERACTION BETWEEN
HEART AND CENTRAL ARTERIES
Abnormalities of the contour of the pulse in Bright’s
disease had been described as early as 1872 by Mahomed
[28], and this has recently been analyzed with modern
methodology by London et al [29–31]. Using Fourier
analysis it can be calculated that the modulus of aortic
impedance is increased. As a consequence, energy is lost in
pressure and flow pulsations, and uncoupling between the
Fig. 4. (A) Capillary density in the heart.
(Semithin section; magnification A-C 1:500).
(b) Reduced capillary density in the heart of a
subtotally nephrectomized rat with renal failure
of 12 weeks duration. (C) Normalization of
capillary density in the heart of a subtotally
nephrectomized rat treated with the selective
ET-1 receptor blocker LU 135252.
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left ventricle and the systemic circulation is noted, in
striking analogy to the changes seen in aging [32, 33]. The
analogies in this respect have led to the idea that to some
extent uremia is a form of accelerated aging [26, 33], and
there may be, at least in part, a common molecular basis
through cumulation of advanced glycation end products
and oxidation. The abnormality of the pulse contour with
an exaggerated systolic peak and an exaggerated diastolic
trough has quite unfavorable repercussions on LV perfor-
mance. On the one hand, peak systolic pressure and by
implication wall stress will be increased in the LV, aug-
menting the stroke work index and contributing to LV
hypertrophy. At the same time, the decrease in diastolic
aortic pressure is accelerated in the non-compliant stiff
aorta of the uremic patient. Since coronary perfusion
occurs only during diastole, low diastolic perfusion pressure
will compromise coronary blood flow in the very heart, the
oxygen demand of which is high because of increased
stroke work.
The systolic overshoot and end diastolic undershoot of
pressure is explained in part also by increased pulse wave
velocity [31]. Because travel time is reduced, the wave that
has been reflected in the periphery will arrive in systole
(instead of in diastole). As a consequence, LV stroke work
is further augmented.
In uremia, striking structural abnormalities of the central
arteries are noted. In the model of subtotally nephrecto-
mized male Sprague-Dawley rats, as early as eight weeks
after the operation Amann et al found marked smooth
muscle cell hyperplasia, smooth muscle cell hypertrophy, a
decrease in elastic fiber content and a substantial increase
in collagen fiber content of the aortic wall (Table 4) [34]. At
the ultrastructural level this was accompanied by a striking
derangement of the normally regular bedding of elastic










TGFb RI 2 2
Abbreviations are: VEGF, vascular epithelial growth factor; PDGF,
platelet-derived growth factor; TGF, transforming growth factor; ND, not
detectible. Symbols are: (2) no difference subtotally nephrectomized vs.
control; (1) P , 0.05 subtotally nephrectomized . control; (11) P ,
0.01 subtotally nephrectomized . control.
Table 4. Aortic cell hypertrophy and hyperplasia and deranged wall





Systolic BP 117 6 9 119 6 9
mm Hg
Aortic media cells per mm
aortic segment (x103)
281 6 60 470 6 110a
Volume of aortic media
smooth muscle cells m3
85.5 6 14.7 97.7 6 5.8a
Elastic fiber volume
density [VV] %
63.9 6 3.9 52.3 6 2.5a
Collagen fiber volume
density [VV] %
31.9 6 4.0 41.4 6 2.3a
a P , 0.05 vs. sham operated control
Fig. 4. Continued.
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fibers (Fig. 5). The molecular mechanisms associated with
remodeling of aortic structure are currently under investi-
gation. It is of interest that renin mRNA expression was
found to be increased in the adventitial tissue (unpublished
studies) of subtotally nephrectomized rats.
INTERVENTIONS TO REVERSE OR PREVENT LEFT
VENTRICULAR HYPERTROPHY
In contrast to essential hypertension [35], there is little
information on reversal of LVH in dialysis patients. It is
plausible to assume that reducing blood pressure will
ultimately result in reduction of LVH, or at least will
prevent its increase. In dialysis patients Canella et al
observed reduction of LVH by echocardiography after 24
months of treatment including the ACE inhibitor lisinopril
[36]. It is uncertain whether this is due to a specific effect of
ACE inhibition or the nonspecific effect of blood pressure
lowering. The importance of reversing increased preload is
illustrated by the observation of O¨zkahya et al, who showed
that reversal of hypervolemia through reduced dietary
intake of sodium and ultrafiltration caused a reduction of
LVH in dialysis patients even with no further use of
antihypertensive agents [37].
The issue arises as to whether the reversal of LVH is
beneficial with respect to patient survival. While there is a
wealth of information on this point in patients with essen-
tial hypertension [35], no controlled information is avail-
able in dialyzed patients. Nevertheless, clinical common
sense makes this assumption plausible, particularly in view
of the fact that in observational studies LVH is an inde-
pendent predictor of cardiac death [11].
Considering the findings of Stefanski et al, however, it
would appear to be a rational strategy not to wait for LVH
to occur before trying to reverse it [8]. It would be more
logical to prevent its appearance by preemptive treatment.
DIALYSIS PATIENTS WITH LEFT VENTRICULAR
HYPERTROPHY
As shown in Table 5, some aspects of hemodialysis may
cause adverse effects in the patient with LVH [12].
Fig. 5. (A) Normal aortic architecture in a sham operated control animal. (Semithin section; magnification A-B, 1:700). (B) Wall thickening of the
aorta with an increase in cell number and extracellular matrix content in a subtotally nephrectomized rat with renal failure of eight weeks duration.
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On the one hand, ultrafiltration (and if acetate is used,
vasodilation) will reduce LV filling pressures, which re-
duces the stroke volume and thus predispose the patient to
intradialytic hypotension.
Second, sympathetic activation as a consequence of
ultrafiltration will reduce the duration of diastole. Since
coronary perfusion occurs exclusively during diastole,
shortening of the diastole in patients with tachycardia will
compromise coronary perfusion and expose the patient to
the risk of cardiac ischemia.
Furthermore, compensatory sympathetic activation in
response to ultrafiltration is definitely undesirable. In pa-
tients with cardiac failure, catecholamines are a strong
predictor of cardiac death [38]. Indirect evidence also
points to a potentially adverse role of sympathetic overac-
tivity in dialyzed patients, where sympathetic tone is high to
begin with as a consequence of stimulatory afferent signals
emerging from the kidney [39, 40]. In a prospective trial in
dialyzed diabetic patients, it was found that beta blockers
were less frequently used in patients who subsequently died
from cardiac causes than in patients who survived [14].
Based on these and other observations, Zuanetti et al
recently castigated the infrequent use of beta blockers in
dialyzed diabetic (and non-diabetic) patients [41].
Finally, with the use of conventional dialysate calcium
concentrations (7 mg/dl) the plasma ionized calcium con-
centration increases, thus increasing inotropy as docu-
mented in controlled studies [42]. This effect is clearly
unwanted, because it increases myocardial oxygen demand.
What consequences can be drawn from the above con-
siderations?
As recently summarized by Wizemann, in the patient
with cardiac disease (and with LVH), the dialysis procedure
should be adapted in such a fashion that slow rates of
ultrafiltration are selected. This implies longer or more
frequent dialysis sessions or both, and also that anemia is
corrected, tachycardia is avoided by slow ultrafiltration or
administration of beta blockers, and a dialysate calcium
concentration is selected that avoids an increase in cardiac
inotropy during dialysis sessions [43].
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